Date: 23rd February-2026

SURGICAL TREATMENT STRATEGY FOR STOMACH CANCER

Ibodulayeva Zilola
Teacher of public health technical college named after Republic No. 1 Abu Ali Ibn Sina

Annotation: This article examines contemporary surgical treatment strategies for stomach cancer within the framework of multidisciplinary oncologic management. The paper analyzes the role of surgery as the primary curative modality for resectable gastric cancer, emphasizing the importance of achieving R0 resection and adequate lymphadenectomy for accurate staging and improved survival outcomes. Various surgical approaches—including distal, total, and proximal gastrectomy—are discussed in relation to tumor localization, disease stage, and patient-specific factors. The study also highlights the evolution of minimally invasive techniques such as laparoscopic and robotic-assisted gastrectomy, outlining their clinical benefits and oncological safety. Furthermore, the integration of perioperative chemotherapy, enhanced recovery protocols, and personalized treatment planning is evaluated as essential components of modern surgical strategy. The findings underscore that optimal outcomes in stomach cancer management require evidence-based surgical decision-making, multidisciplinary collaboration, and continuous technological advancement.

Keywords: Stomach cancer, gastric cancer, surgical treatment strategy, gastrectomy, lymphadenectomy, D2 dissection, minimally invasive surgery, laparoscopic gastrectomy, robotic surgery, perioperative chemotherapy, R0 resection, multidisciplinary oncology.

Gastric cancer remains one of the most significant global health challenges in contemporary oncology and surgical practice. Despite advances in diagnostic technologies, systemic therapies, and preventive strategies, stomach cancer continues to rank among the leading causes of cancer-related mortality worldwide. The complexity of its biological behavior, frequent late-stage presentation, and heterogeneity in histopathological and molecular characteristics make the management of gastric cancer particularly demanding. Within the multidisciplinary framework of cancer care, surgical treatment remains the cornerstone and only potentially curative modality for localized and resectable disease. Consequently, the development and optimization of surgical treatment strategies for stomach cancer represent a critical area of clinical research and practice. Gastric cancer encompasses a spectrum of malignant epithelial tumors arising from the gastric mucosa, with adenocarcinoma accounting for more than 90% of cases. The disease exhibits marked geographic variation in incidence, with higher prevalence observed in East Asia, Eastern Europe, and parts of South America. Environmental factors such as dietary habits, smoking, Helicobacter pylori infection, and genetic predisposition contribute significantly to its pathogenesis. Moreover, molecular classification systems have revealed distinct biological subtypes, including chromosomal instability, microsatellite instability,

genomically stable, and Epstein–Barr virus–associated tumors. These subtypes demonstrate variable prognostic outcomes and therapeutic responsiveness, further emphasizing the necessity for individualized treatment strategies. One of the major challenges in gastric cancer management is the late presentation of symptoms. Early-stage disease is frequently asymptomatic or manifests with nonspecific complaints such as epigastric discomfort, dyspepsia, or mild weight loss. As a result, many patients are diagnosed at advanced stages when curative surgical options are limited. In contrast, countries with established screening programs have reported improved detection of early gastric cancer, significantly enhancing long-term survival rates. Early identification allows for less invasive surgical interventions and, in selected cases, endoscopic resection techniques.

The surgical treatment of stomach cancer has undergone substantial evolution over the past century. Historically, radical gastrectomy with extensive lymphadenectomy was performed with high morbidity and mortality rates. Improvements in anesthesia, perioperative care, blood transfusion practices, and surgical techniques have markedly reduced operative risks. Today, surgical strategy is determined by tumor location, stage, histological type, and patient-related factors such as age, comorbidities, and nutritional status. The primary objective of surgical intervention is complete tumor removal with negative margins (R0 resection) while ensuring adequate lymph node dissection for accurate staging and local disease control. The extent of gastric resection varies according to tumor localization. Distal (subtotal) gastrectomy is generally indicated for tumors located in the antrum and distal body of the stomach, whereas total gastrectomy is recommended for proximal or diffuse lesions. Proximal gastrectomy may be considered in selected early-stage tumors of the upper third of the stomach, though its use remains controversial due to postoperative reflux complications. The choice between these surgical approaches must balance oncological radicality with postoperative functional outcomes and quality of life. Lymphadenectomy constitutes a fundamental component of surgical strategy in gastric cancer. Adequate lymph node dissection improves staging accuracy and may enhance survival by removing micrometastatic disease. The classification of lymphadenectomy into D1, D1+, and D2 dissections reflects the extent of nodal removal. In Eastern countries, particularly Japan and South Korea, D2 lymphadenectomy has become the standard approach for resectable advanced gastric cancer due to favorable survival outcomes demonstrated in large-scale studies. In Western countries, earlier trials raised concerns regarding postoperative morbidity; however, contemporary evidence supports D2 dissection when performed in high-volume centers with experienced surgeons. Minimally invasive surgical techniques have further transformed the treatment landscape. Laparoscopic gastrectomy, initially applied for early gastric cancer, has gained acceptance for selected advanced cases as well. This approach offers benefits including reduced intraoperative blood loss, shorter hospital stay, faster postoperative recovery, and improved cosmetic results without compromising oncological safety. Robotic-assisted gastrectomy represents another technological advancement, providing enhanced dexterity, three-

dimensional visualization, and improved precision in lymphadenectomy. Ongoing clinical trials continue to evaluate the long-term oncological equivalence of these techniques compared to open surgery. In addition to surgical technique, perioperative management plays a pivotal role in treatment strategy. Multimodal therapy integrating surgery with chemotherapy and, in selected cases, radiotherapy has significantly improved survival outcomes. Perioperative chemotherapy has become a standard component in many treatment protocols for locally advanced gastric cancer, aiming to downstage tumors, eradicate micrometastases, and increase R0 resection rates. The integration of systemic therapy into surgical planning requires close collaboration among surgeons, medical oncologists, radiologists, and pathologists. Another critical aspect of surgical treatment strategy is the management of advanced or metastatic disease. While surgery remains primarily curative in intent, palliative surgical interventions may be indicated to alleviate symptoms such as gastric outlet obstruction, bleeding, or perforation. In carefully selected patients with limited metastatic spread, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has been explored, although its role remains under investigation. Postoperative complications significantly influence treatment outcomes and patient quality of life. Anastomotic leakage, pancreatic fistula, delayed gastric emptying, and nutritional deficiencies are among the potential adverse events. Enhanced Recovery After Surgery (ERAS) protocols have been introduced to reduce surgical stress, shorten hospitalization, and accelerate functional recovery. Nutritional support before and after gastrectomy is particularly important, as many patients present with malnutrition due to tumor-related anorexia and weight loss. Quality of life considerations are increasingly recognized as integral components of surgical decision-making. Total gastrectomy, while oncologically appropriate in certain cases, results in lifelong alterations in digestion, vitamin absorption, and eating patterns. Reconstruction techniques such as Roux-en-Y esophagojejunostomy aim to optimize postoperative function, yet long-term follow-up is essential to manage metabolic and nutritional sequelae. Therefore, modern surgical treatment strategy emphasizes not only survival outcomes but also functional preservation and patient-centered care. Technological innovations, including intraoperative fluorescence imaging, sentinel lymph node navigation, and artificial intelligence–assisted surgical planning, are shaping the future of gastric cancer surgery. Molecular profiling and precision medicine approaches may further refine patient selection for tailored surgical and systemic treatments. The continuous integration of research findings into clinical guidelines ensures that surgical strategies evolve in accordance with evidence-based practice. In summary, surgical treatment strategy for stomach cancer represents a dynamic and multifaceted field that integrates oncological principles, technological advancements, and multidisciplinary collaboration. Surgery remains the central therapeutic modality for resectable disease, with the extent of resection and lymphadenectomy determined by tumor characteristics and patient factors. The transition from radical open procedures to minimally invasive and function-preserving approaches reflects progress in both surgical science and patient care philosophy. As research continues to elucidate tumor biology and

optimize perioperative management, the refinement of surgical strategies will remain fundamental to improving survival rates and quality of life for patients with gastric cancer. The surgical treatment strategy for stomach cancer remains a central pillar in the comprehensive management of this complex and life-threatening disease. Despite significant advances in systemic therapies, early detection programs, and molecular diagnostics, surgery continues to offer the only potentially curative option for patients with localized and resectable gastric cancer. The evolution of surgical approaches over recent decades reflects a continuous effort to balance oncological radicality with functional preservation, reduced morbidity, and improved quality of life. A fundamental objective of surgical management is the achievement of an R0 resection—complete tumor removal with negative microscopic margins—combined with adequate lymph node dissection for accurate staging and locoregional disease control. Evidence consistently demonstrates that both the completeness of resection and the extent of lymphadenectomy significantly influence long-term survival outcomes. In this context, D2 lymph node dissection has emerged as the standard of care in experienced centers, provided that it is performed with appropriate surgical expertise and perioperative support to minimize complications. The choice of surgical procedure—distal gastrectomy, total gastrectomy, or proximal gastrectomy—is determined by tumor location, stage, histopathological features, and patient-related factors. Personalized surgical planning has become increasingly important, as patient age, nutritional status, comorbidities, and performance status directly affect perioperative risk and recovery. Modern treatment strategies emphasize individualized decision-making within a multidisciplinary framework that includes surgeons, medical oncologists, radiologists, pathologists, and supportive care specialists. Minimally invasive techniques, including laparoscopic and robotic-assisted gastrectomy, have significantly transformed surgical practice. These approaches have demonstrated comparable oncological outcomes to open surgery in selected patients, while offering advantages such as reduced intraoperative blood loss, shorter hospital stays, faster recovery, and improved postoperative comfort. As surgical technology advances, the integration of enhanced visualization systems, precision instrumentation, and real-time imaging continues to refine operative accuracy and safety. Multimodal therapy has become a cornerstone in the management of locally advanced gastric cancer. The integration of perioperative chemotherapy has improved resection rates and overall survival by targeting micrometastatic disease and facilitating tumor downstaging. Surgical strategy is therefore no longer considered in isolation but as part of a comprehensive treatment algorithm that optimizes both local and systemic disease control. Close coordination between surgical and medical oncology teams ensures appropriate patient selection and treatment sequencing. The management of advanced or metastatic gastric cancer remains challenging. While curative surgery is rarely feasible in this setting, palliative surgical interventions may provide significant symptom relief and enhance quality of life. In highly selected cases, cytoreductive surgery combined with intraperitoneal chemotherapy has shown potential benefit, although further research is needed to define its precise indications and long-term

efficacy. Postoperative outcomes depend not only on surgical technique but also on perioperative care and rehabilitation. The implementation of Enhanced Recovery After Surgery (ERAS) protocols has reduced postoperative complications, accelerated functional recovery, and shortened hospital stays. Nutritional management is particularly critical following gastrectomy, as patients are at risk of weight loss, vitamin deficiencies, and metabolic disturbances. Long-term follow-up is essential to monitor recurrence, manage complications, and support survivorship.Importantly, modern surgical strategies increasingly incorporate quality-of-life considerations into decision-making processes. While survival remains the primary goal, preserving digestive function, minimizing long-term morbidity, and supporting psychological well-being are equally important. Advances in reconstructive techniques and supportive care have contributed to improved functional outcomes, but continued research is required to optimize postoperative adaptation and nutritional support. Looking forward, the future of gastric cancer surgery lies in precision medicine and technological innovation. Molecular profiling may enable more accurate risk stratification and tailored therapeutic approaches. The use of artificial intelligence in imaging, staging, and intraoperative guidance holds promise for enhancing diagnostic accuracy and surgical planning. Sentinel lymph node mapping and fluorescence-guided surgery may further refine the extent of lymphadenectomy and reduce unnecessary tissue trauma. In conclusion, the surgical treatment strategy for stomach cancer is a dynamic and evolving field grounded in oncological principles, technological progress, and multidisciplinary collaboration. Achieving optimal outcomes requires careful patient selection, meticulous operative technique, appropriate integration of systemic therapy, and comprehensive perioperative care. As scientific knowledge expands and clinical practice continues to advance, the refinement of surgical strategies will remain essential in improving survival rates and enhancing the quality of life for patients affected by gastric cancer.

REFERENCES:

1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2020). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians, 70*(4), 313–331.
2. Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C. T., & Lordick, F. (2020). Gastric cancer. *The Lancet, 396*(10251), 635–648.
3. Japanese Gastric Cancer Association. (2021). Japanese gastric cancer treatment guidelines 2018 (5th edition). *Gastric Cancer, 24*(1), 1–21.
4. National Comprehensive Cancer Network (NCCN). (2023). *NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer*. Version 2.2023.
5. Ajani, J. A., D'Amico, T. A., Bentrem, D. J., et al. (2017). Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network, 15*(3), 298–329.

6. Cunningham, D., Allum, W. H., Stenning, S. P., et al. (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *The New England Journal of Medicine, 355*(1), 11–20.
7. Al-Batran, S. E., Hofheinz, R. D., Pauligk, C., et al. (2019). Perioperative chemotherapy with FLOT versus ECF/ECX for resectable gastric or gastro-esophageal junction adenocarcinoma (FLOT4 trial). *The Lancet, 393*(10184), 1948–1957.
8. Songun, I., Putter, H., Kranenbarg, E. M., Sasako, M., & van de Velde, C. J. H. (2010). Surgical treatment of gastric cancer: 15-year follow-up results of the randomized nationwide Dutch D1D2 trial. *The Lancet Oncology, 11*(5), 439–449.
9. Kitano, S., Shiraishi, N., Uyama, I., Sugihara, K., & Tanigawa, N. (2007). A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan. *Annals of Surgery, 245*(1), 68–72.
10. Hyung, W. J., Yang, H. K., Park, Y. K., et al. (2020). Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: The KLASS-02 randomized clinical trial. *Journal of Clinical Oncology, 38*(28), 3304–3313.
11. Strong, V. E., Russo, A., Yoon, S. S., et al. (2009). Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. *Annals of Surgery, 251*(4), 640–646.
12. Degiuli, M., Sasako, M., Ponti, A., et al. (2014). Randomized clinical trial comparing survival after D1 versus D2 gastrectomy for gastric cancer. *British Journal of Surgery, 101*(2), 23–31.